Keyword: Donald Trump

Measures in Trump's 2020 budget aim to incentivize lower list prices, promote competition and more.

Novartis' $1.2 million consulting deal with President Donald Trump's former attorney faced scrutiny again Wednesday.

A new bill to legalize insulin imports comes amid a congressional probe of pricing directed at insulin makers Sanofi, Novo Nordisk and Eli Lilly.

Catalyst is unfazed by a letter from Sen. Bernie Sanders demanding that it justify the cost of its rare-disease drug Firdapse, confirmed at $300K after discounts.

Johnson & Johnson is the first pharma to announce it will put drug list prices directly in TV ads, self-regulating ahead of a proposed regulation.

Sen. Charles Grassley, R-Iowa, vowed to haul pharma CEOs into Senate drug-pricing hearings. Now, several have heeded the call.

As the Trump administration weighs ending rebates to PBMs, their trade group has debuted ads asserting the cost-cutting value of the industry middlemen.

A bipartisan push to lower drug prices could threaten the industry's ability to drive earnings growth, some analysts warn.

The Trump proposal requiring pharma companies to add drug prices to advertising might not work according to plan.

Past pharma mergers have spawned price hikes, two U.S. representatives argue—and DTC and DOJ need to weigh the $74 billion deal with that in mind.